Keep Me Logged In
ImmunoGen president and CEO Daniel Junius discusses the potential for its cancer treatment Kadcyla, and whether investors should be concerned about toxicity problems in some of its drug trials.
Got a confidential news tip? We want to hear from you.
Sign up for free newsletters and get more CNBC delivered to your inbox
© 2018 CNBC LLC. All Rights Reserved. A Division of NBCUniversal
Data is a real-time snapshot *Data is delayed at least 15 minutes. Global Business and Financial News, Stock Quotes, and Market Data and Analysis.
Data also provided by